Dedifferentiation, Transdifferentiation, and Reprogramming: Future Directions in Regenerative Medicine

Cristina Eguizabal, PhD¹ Nuria Montserrat, PhD¹ Anna Veiga, PhD¹,²
Juan Carlos Izpisua Belmonte, PhD¹,³

¹Center for Regenerative Medicine in Barcelona
²Reproductive Medicine Service, Institut Universitari Dexeus, Barcelona, Spain
³Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, California

Semin Reprod Med 2013;31:82–94

Abstract

The main goal of regenerative medicine is to replace damaged tissue. To do this it is necessary to understand in detail the whole regeneration process including differentiated cells that can be converted into progenitor cells (dedifferentiation), cells that can switch into another cell type (transdifferentiation), and somatic cells that can be induced to become pluripotent cells (reprogramming). By studying the regenerative processes in both nonmammal and mammal models, natural or artificial processes could underscore the molecular and cellular mechanisms behind these phenomena and be used to create future regenerative strategies for humans.

Keywords
- regenerative medicine
- stem cells
- dedifferentiation
- transdifferentiation
- reprogramming

To understand any regenerative system, it is crucial to find the cellular origins of renewed tissues. Using techniques like genetic lineage tracing and single-cell transplantation helps to identify the route of regenerative sources. These tools were developed first in nonmammal models (flies, amphibians, and fish) and then in mammal models like mice. The source of cells during regeneration in most cases is either stem cells or progenitor cells, or the dedifferentiated or transdifferentiated cells within the tissue of origin. Another process related to regenerative therapies is reprogramming: somatic cells that can be converted into stem cells, known as induced pluripotent stem cells (iPSs). These artificial stem cells are suitable for several purposes: basic research, drug screening, disease modeling, or autologous cell therapy.

The promising future of regenerative medicine is to replace or regenerate tissues or organs to restore or reestablish normal cell function. To do so, it is necessary to understand the three regenerative processes: dedifferentiation, transdifferentiation, and reprogramming. By using the model developed by Waddington¹,² (Fig. 1), it is possible to understand the epigenetic status and the developmental potential of each cell during these processes. This modified schematic representation explains graphically how cells lose potency and differentiate and how they can revert to pluripotency (reprogramming) or switch lineages (dedifferentiation and transdifferentiation).

We synthesize the studies of different model systems to highlight recent insights that are integrating the field. Whereas previous reviews largely focused on specific animal models, molecular pathways, or only on one regenerative route, our aim is to combine the three regenerative routes in several species and discuss future directions in regenerative medicine.

Dedifferentiation

Dedifferentiation is the reverse developmental process in which differentiated cells with specialized functions become undifferentiated progenitor cells. Dedifferentiation and subsequent proliferation provide the basis for tissue regeneration and the formation of new stem cell lineages.

In Vivo Dedifferentiation

Historically, the first evidence of dedifferentiation during the regeneration process was found in plants.³ Basically, it can be divided into different types: the regeneration of a tissue...
structure lost after an injury, the de novo generation of a new tissue structure not present before the injury, and the regeneration of the whole plant from a single somatic cell. Recent studies on the generation of callus have shown that it regenerates due to a preexisting pluripotent stem cell population instead of a dedifferentiation process. More studies are still needed to evaluate this discrepancy.

In nonmammalian vertebrates, there are several examples of dedifferentiation; one of them is bone regeneration via dedifferentiation of the osteoblast in zebrafish fin. Knopf and colleagues monitored osteoblast differentiation in the regenerating fin using a transgenic system expressing fluorescent proteins under the control of promoters of early, intermediate, and late osteoblast-specific genes (RUNX2, SP7, and BGLAP [osteocalcin]). Their elegant study showed that in a response to the amputation, mature osteoblasts dedifferentiate, become proliferative, and migrate distally to form outer regions of the regeneration of blastema of fin rays.

Another example of dedifferentiation occurs during heart regeneration in zebrafish. Jopling and colleagues described that zebrafish heart can fully regenerate up to 20% after amputation in the ventricle. To explain these data, the authors generated induced green fluorescence protein (GFP) transgenic zebrafish under cardiomyocyte-specific promoters (mlic2a and gata4). During this regeneration process, fully differentiated cardiomyocytes can dedifferentiate and proliferate, regenerating the missing part of the ventricle. GFP-labeled cells indicated that the newly generated cardiomyocytes originated from existing GFP cardiomyocytes and not from a source of progenitors.

Another good example of dedifferentiation is limb regeneration in urodeles (salamander). At first the blastema (group of cells that initiates the regenerative process) was regarded as a homogeneous cell population, but it was later demonstrated to be a heterogeneous cell population containing progenitor cells with restricted potential. A specific cell lineage analysis revealed that the regenerating cells maintaining the memory of the earlier cellular identity give rise to tissues only within their original lineage. A recent controversial study in Xenopus limb regeneration confirmed the important role of SALL4 in the dedifferentiation and maintenance of the blastema cells in an undifferentiated state. More studies on limb regeneration are needed to elucidate the real mechanisms involved in limb regeneration in amphibians.

In the case of tail regeneration in the axolotl, tracking fluorescent-labeled single muscle fibers and observing the mononuclear state of muscle fibers cells as a “less differentiated” state, muscle cells confirmed the dedifferentiation of mature fibers. In the same manner, authors observed an increase of the transcription factor MSX-1, known to be expressed in early development during epithelial-mesenchymal transition. Taken together, all of this provides evidence that the terminally differentiated myotubes dedifferentiated toward multipotent cells.

The dedifferentiation process has been shown to be related to the entry of the regenerating cells into the cell cycle. It has been observed that during regenerative dedifferentiation, the tumor suppressor retinoblastoma protein (RB) plays a key role in the reentry of the cells into cell cycle. Along these lines, it has been shown that Drosophila melanogaster mutants for RB and Hippo (a member of the STE20 family of protein kinases) maintain a normal neuronal differentiation program. However, the cells do not retain their differentiated status. They dedifferentiate to an earlier eye-precursor stage showing unrestricted proliferation. So far, it seems that dedifferentiation and the cell cycle processes are distinct from one another and that RB also plays an important role in maintaining the differentiated status of the cell.

In mammals, the capacity of regeneration following the dedifferentiation strategy is limited. However, it has been observed that in the mouse model, Schwann cells possess the natural ability to regenerate. During development, Schwann

![Figure 1](image_url)
precursors dedifferentiate toward immature Schwann cells and then finally differentiate into mature myelinating or nonmyelinating Schwann cells. The precursor cell proliferates, whereas the mature cell does not. After nerve injury, Schwann cells dedifferentiated and proliferated at the same time. After local damage, mature Schwann cells lose contact with the axon caused by local damage, they dedifferentiate, and, before proliferating, they begin again to express genes that are linked to immature Schwann cells (NOTCH and JUN) causing the demyelination of the mature cells and promoting the dedifferentiation.

**In Vitro Dedifferentiation**

Myotubes can dedifferentiate and proliferate in newts in vivo, whereas this has not been demonstrated in mice. Two genes have been shown to be crucial for this process (MYOD and MYOG [myogenin]). After treating mouse myotubes with extracts from regenerating limbs of newts, these two genes were downregulated, which allows myotubes to dedifferentiate and proliferate.

Several examples of dedifferentiation in humans have recently been published. Human thyroid follicular cells can be dedifferentiated into multilineage progenitor cells by culturing them in serum-free conditions. It has been reported that after 4 weeks in culture, the human thyroid follicular cells gain the expression of typical markers of progenitor cells (STRO-1, vimentin) and lose other differentiation markers (cytokeratin-18)²⁶ (Fig. 2B).

Human epidermal keratinocytes dedifferentiate into precursor cells in vitro in the presence of basic fibroblast growth factor (bFGF) with no external gene intervention. After seven passages the terminally differentiated keratinocytes initiate dedifferentiation by the re-expression of biological markers of native keratinocyte stem cells including β1-integrin, CK19, and CK14²⁷ (Fig. 2C).

Recent data showed that in the presence of epidermal growth factor in an in vitro culture system, adult human islet cells could be converted back into duct-like epithelial structures. During this islet cell dedifferentiation plasticity, some genes have been identified as “plasticity inducers” (JNK, AKT, and ERK)²⁸ (Fig. 2D).

Fat cells provide another example of in vitro dedifferentiation in humans. Mature adipocytes have been considered as a terminally differentiated lineage with no capacity for proliferation. However, a simple ceiling culture system allows mature adipocytes to go back into lipid-free fibroblast-like cells, named dedifferentiated fat (DFAT). These DFAT have the features of multipotent stem cells with adipogenic, osteogenic, chondrogenic, and myogenic potential²⁹ (Fig. 2E).

Studies on the role of RB and RB-like protein demonstrated that dedifferentiation of mature cardiomyocytes can facilitate their proliferation in hypertrophic hearts.³⁰ Further studies...
using a combination of FGF1 stimulation and p38 MAPK inhibition can induce mammalian cardiomyocytes to dedifferentiate and to disassemble their contractile machinery before proliferating. However, other experimental data suggest that such dedifferentiation may not be necessary for cardiomyocyte proliferation. It has been demonstrated that proliferation can be promoted by neuregulin, an extracellular ligand for ERB receptor, important during cardiomyocyte development, that also reenters cardiomyocytes into the cell cycle.

Transdifferentiation

Transdifferentiation means the irreversible conversion of cells from one differentiated cell type to another. Normally dedifferentiation and cell division are essential intermediate processes in the switch in phenotype, but they may not be obligatory in all cases. Some authors have considered that it does not occur at all in nature. There is good evidence, however, that it does occur in some cases, particularly in situations where missing parts regenerate in animals.

In Vivo Transdifferentiation

One well-known example of in vivo transdifferentiation is the Wolffian regeneration of the lens of various species of urodele amphibia (newts and salamanders) and anuran (frogs). In these species, after removal of the lens of the eye, new pigmented epithelial cells (PECs) of the lens regenerate and further differentiate to form a new lens. This regeneration implicates the inactivation of RB allowing the cells to reenter the cell cycle. Recently, Day and Beck showed that WNT and bone morphogenetic protein signaling pathways are needed for the transdifferentiation from cornea to lens, with the PITX and WNT genes crucial for this process.

Another well-established example of transdifferentiation is the regeneration of striated muscle in the jellyfish involving the expression of the homeobox gene MSX. Although transdifferentiation is rare in mammals, the musculature of the mouse esophagus has been found to convert from smooth muscle in the fetus to skeletal muscle during early postnatal development. During this process, smooth muscle cells transform back into myoblasts. They then line up and fuse to form myotubes that become cylindrical skeletal muscle fibers (►Fig. 3A).

Figure 3 In vivo and in vitro transdifferentiation in mammals. (A) The musculature of the mouse esophagus was found to convert from smooth muscle in the fetus to skeletal muscle during early postnatal development. (B) Hepatic oval stem cells transdifferentiate into functional endocrine cells. (C) Adult hepatocytes transdifferentiate into pancreatic cells. (D) Pancreatic exocrine cells transdifferentiate into insulin-producing β cells. (E) Transdifferentiation of β cells into macrophages. (F) Fibroblasts transdifferentiate into neurons, cardiomyocytes, and blood progenitors. LIF, leukemia inhibitory factor.
Another example of transdifferentiation is provided by the liver and the pancreas. These two organs arise from nearby regions of the endodermal epithelium. The FGF signaling pathway has been demonstrated to lead the ventral pancreas to express genes of the liver.\(^{44,45}\)

**In Vitro Transdifferentiation**

Recent studies demonstrated that cultures of purified hepatic oval stem cells exhibit the capacity to transdifferentiate into functional endocrine cells, including insulin-secreting cells, after long-term culture with culture conditions similar to those permitting pancreatic stem cells to differentiate to insulin \(\beta\) cells. This transdifferentiation is induced by the removal of leukemia inhibitory factor (LIF) and the increase of glucose concentration in the media. Interestingly, during early stages of the transdifferentiation process, hepatic oval cells show higher levels of expression of the PDX1 gene than terminally pancreatic endocrine hormone-producing cells\(^{46}\) (Fig. 3B). Others have demonstrated that overexpression of PDX1 promotes the transdifferentiation from adult hepatocytes into pancreatic cells inhibiting the transcription factor CCAAT enhancer-binding protein-\(\beta\) (CEBP-\(\beta\)), leading to a decrease of the expression of mature hepatocyte genes such as \(\alpha\)-fetoprotein, glucose-6-phosphate, and albumin\(^{47}\) (Fig. 3C). Moreover, pancreatic exocrine cells have been transdifferentiated into insulin-producing \(\beta\) cells by expressing PDX1, NGN3, and MAFA genes\(^{48-50}\) (Fig. 3D). Another transdifferentiating route that can be used to produce mature insulin-producing \(\beta\) cells is by going through an intermediate cell stage before reaching the complete differentiated cell status. The intermediate cells produce glucagon (produced by \(\alpha\) cells) and insulin (produced by \(\beta\) cells).\(^{51}\)

Another example is the experimental transdifferentiation of \(\beta\) cells into macrophages. It has been described that three transcription factors (E2A, EBF, and PU.1) are involved in the differentiation to \(\beta\) cells during development, which in turn causes the expression of PAX5, which upregulates later specific \(\beta\)-cell genes. However, during differentiation of macrophages CEBPB, CEBP\(\alpha\) and PU.1 are present. It has been reported that forced expression of CEBPB and CEBP\(\alpha\) in differentiated \(\beta\) cells leads to reprogram them into macrophages without significant changes in DNA methylation\(^{52,53}\) (Fig. 3E).

Following a similar strategy, it is possible to transdifferentiate mouse fibroblasts into functional neurons using three transcription factors (ASCL1, BRN2, and MYT1). The exact mechanism involved in this process is still unknown.\(^{54}\) Studies were recently published about the plasticity mechanisms during transdifferentiation of mature neurons. Loy and colleagues identified the P38 gene as the trigger for switching from noradrenergic to cholinergic neurotransmission after exposure to the neurotrophic cytokines ciliary neurotrophic factor and LIF\(^{55}\) (Fig. 3F).

Fibroblasts have also been transdifferentiated into cardiomyocytes using GATA4, MEF2C, and TBX5. GATA4 initiates the process by opening the chromatin, allowing the other transcription factors access\(^{56}\) (Fig. 3F).

It was recently published that treatment with angiotensin receptor blockers (ARBs) in cultured human mesenchymal stem cells (MSCs) improves cardiomyogenic transdifferentiation efficiency both in vivo and in vitro, and transplantation of ARB pretreated cells could be a promising cardiac stem cell source for replacing damaged cardiomyocytes.\(^{57}\)

Human dermal fibroblasts have also been transdifferentiated into granulocytic, monocytic, megakaryocytic, and erythroid lineages with in vivo engraftment capacity using the ectopic expression of OCT4 in the presence of specific cytokine treatment\(^{58}\) (Fig. 3F).

**Reprogramming**

The reversal of the differentiated state of a mature cell to one typical of the undifferentiated embryonic state is known as nuclear reprogramming.\(^{59}\) During this reprogramming process, an erasure and remodeling of epigenetic marks occur such as DNA methylation, histone, and chromatin structure modifications. For a better understanding of this epigenetic event, we first focus on in vivo studies during mammalian development. We then describe the different approaches of in vitro reprogramming such as somatic cell nuclear transfer (SCNT), cell fusion, and spontaneous and direct induced reprogramming.

**In Vivo Nuclear Epigenetic Reprogramming**

From Zygote to Blastocyst

From zygote to blastocyst, cells have to make crucial decisions to allow complete development of the individual. These decisions are related to the activation or silencing of genes in a well-orchestrated manner. The activation or silencing of genes is regulated by epigenetic elements. A good combination of epigenetic elements like DNA methylation, histone modifications, and chromatin structure permit the creation of the correct cells that will form a healthy organism.

The epigenetic program in early mouse development initiates with DNA methylation in the paternal pronucleus of the zygote, followed later by a gradual loss of DNA methylation, and ending by changing the structure of heterochromatin in the inner cell mass (ICM) of the blastocyst linked with X-chromosome reactivation in female embryos. During fertilization, the maternal DNA is surrounded by H100 variant substituting H1 linker histones, probably helping in the decondensation of the maternal chromatin.\(^{60}\) By contrast, paternal DNA is compacted using protamines, and after fertilization the genome starts to be decondensed by histones. The histone variants H2A.L1/L2 present on the heterochromatin in sperm disappear during the protamine/histone replacement just after fertilization.\(^{61,62}\) Also some sperm-specific histone variants (H2A.L1/L2, th2B, H3.3, H2A.X, and H2A.Z) are highly expressed during this process. Following fertilization and the extrusion of the second polar body, the maternal and paternal genomes start to decondense at the pronucleus (PN) 1 stage. The protamines compacting the paternal genome are missing and lacking H3K9me2, H3K9me3, and H3K27me3 heterochromatin histone marks,
whereas these histone modifications are still present in the female pronucleus.\textsuperscript{63,64} Also the H3.3 variant specifically present in the male pronucleus contributes to this epigenetic asymmetry between parental pronuclei.\textsuperscript{65,66}

At the PN2 stage, high levels of DNA methylation are detected in both pronuclei. The loss of the global methylation mark, 5-methyl cytosine (5meC), surprisingly affects only the paternal genome, whereas the levels of maternal DNA methylation remain unaffected.\textsuperscript{64,67,68} This specific paternal demethylation is linked to the lack of repressive histone modification marks: H3K9me2, H3K9me3, and H3K27me3.\textsuperscript{69,70}

The culmination of the epigenetic changes in early development appears in the pluripotent cells of the ICM at the blastocyst stage. The formation of the ICM is related to another epigenetic change, the reactivation of the inactive X chromosome in female embryos\textsuperscript{71,72} (\textit{Fig. 4}).

**Germline**

The germline is a unique cell type that has the capability to give rise to gametes. The germline is a direct derivation of the pluripotent epiblast of the postimplantation embryo. Following specification, the primordial germ cells (PGCs) establish a specific transcriptional network similar to the networks of the pluripotent embryonic stem (ES) cells.\textsuperscript{73}

In mice, at 8.5 days postcoitum (dpc) PGCs start the migratory process toward the future gonads, the genital ridges. This migration ends around 10.5 dpc. In females, the PGCs downregulate the expression of Xist from the inactive X chromosome (Xi), later followed by a progressive reactivation of Xi-linked silent genes that is completed at 14.5 dpc\textsuperscript{74,75} (\textit{Fig. 3}). Once the PGCs are in the genital ridges, the germ cells undergo an epigenetic reprogramming. This reprogramming involves genomewide DNA demethylation, changes in chromatin structure, and loss of several histone modification marks.\textsuperscript{69,76} The DNA methylation affects both single-copy genes (imprinted and nonimprinted) as well as repetitive elements happening only in a window of time lasting a few hours. Interestingly, the onset of DNA demethylation precedes the onset of chromatin changes like the loss of signal for linker histones, H3K9me3, H3K27me3, H2A/H4 R3me2s, and other histone modification marks (\textit{Fig. 4}). Both processes occur in the G2 phase of the cell cycle, demonstrating that the genomewide DNA methylation is an active process.

---

\textsuperscript{1} Figure 4 Schematic diagram of the in vivo and in vitro epigenetic changes during epigenetic reprogramming in early mouse development and germline. EG cells, embryonic germ cells; hpf, hours post fertilization; PGCs, primordial germ cells.
Recently, it was proposed that a base excision DNA repair (BER) element in the active DNA demethylation could be involved in PGC epigenetic reprogramming. However, the exact molecular details of this active DNA demethylation in the germline still remain unknown. This epigenetic reprogramming is needed in this specialized cell type for preventing the formation of aberrant gametes.

**In Vitro Nuclear Epigenetic Reprogramming**

**Somatic Cell Nuclear Transfer**

The process of SCNT consists of transferring a somatic nucleus into an enucleated oocyte. After being inserted into the oocyte, the somatic cell nucleus is reprogrammed by the cytoplasm of the host oocyte cell. The oocyte, now containing the somatic cell's nucleus, is stimulated with a shock and begins to divide. After many mitotic divisions, this single cell forms a blastocyst with almost identical DNA to the original organism. SCNT can be performed for two different aims: reproductive SCNT with the objective of obtaining cloned animals and therapeutic SCNT with the objective of obtaining embryonic stem cells.

The earliest evidence of nuclear reprogramming in frogs came from the transplantation of the nucleus of gastrula embryo cells into enucleated frog eggs, creating a normal swimming tadpole of *Ranna pipiens* in 1952 by Briggs and King. However, they found later that the transfer of an older nucleus of gastrula embryo cells resulted in an abnormal embryo, concluding that cell differentiation involves irreversible nuclear changes. After this, similar experiments were performed with eggs using *Xenopus leavis* by Gurdon. In those experiments, it was found that even when the *Xenopus* nuclei were transplanted from fully differentiated cells (intestinal epithelial cells), normal fertile frogs of both sexes could be obtained. Taken together, these first advances pointed out that the process of cell differentiation could be reversible and did not require irreversible nuclear changes.

One of the most important advances in the field of developmental biology was the publication by Wilmut et al in 1998 of the birth of a cloned sheep (Dolly) by transplanting the nucleus of an adult somatic mammary gland cell into an enucleated oocyte (Fig. 5A). Later reports showed that it is possible to successfully clone a mammal (mouse) from an adult postmitotic cell (neuron), suggesting that this might also work in humans.

In the last 10 years, progress has been made producing “clones” for reproductive purposes in several species—cattle, goats, mice, and pigs—using the nucleus of adult cells (lymphocytes and postmitotic neurons) in the transfer. Another variant of SCNT is to create interspecies clones like the combination between *Bos indicus* and *Bos taurus* or between tiger and cat. However, in these cases, the interspecies embryo transfers contribute to perinatal death.

Embryonic stem cells from cloned embryos have been derived in several species such as mouse, rabbit, and pig. An important step in this direction has been the

---

**Figure 5** In vitro nuclear epigenetic reprogramming. Approaches to restore pluripotency in somatic cells. (A) Somatic nuclear transfer cells (SNTCs). (B) Cell fusion forming heterokaryons or proliferative hybrids. EG cells, embryonic germ cells; ES cell, embryonic stem cell.
derivation of monkey embryonic stem cells from blastocysts obtained after the transplantation of an adult nucleus into an enucleated monkey oocyte for regenerative purposes.98

Since Dolly the sheep was born, many experiments have been performed in mammals using different donor nuclei cell types (from stem cells to fetal and adult somatic cells) and several donor recipient oocytes at different cell cycle stages,99 but unfortunately the efficiency of SCNT has not been improved, limiting the applicability of this method. A fundamental problem is related to the imperfections of the reprogramming following transfer of the nucleus. One reason for this low efficiency is that the cell cycles between donor cells and recipient oocytes should be synchronized. Also the enucleated oocytes must carry the diploid DNA contents after their artificial activation (MII phase). The G0/G1 is the most adequate and successful phase for the donor cell. Also M- and S-phase donor cells can be reprogrammed in the MII enucleated oocyte with less efficiency than the previous combination.99–101

The second reason for the low efficiency of SCNT can be the donor cell type. In the bovine, Kato and colleagues compared 39 cell types from adults, newborns, and fetuses of both sexes to perform SCNT, but no difference was observed.102 Later studies using adult stem cells, such as bone marrow MSCs and hematopoietic stem cells,103,104 indicated that the low efficiency observed in SCNT does not only depend on the cell type. It has been shown that it is difficult to complete reprogramming of nuclear transferred oocytes using epigenetic modification of DNA, such as methylation of the imprinted genes in the donor cells. It might be suggested that imprinting status is more important for the success of the cloning than the origin of the donor cells. It is possible that successful cloning requires the use of donor cells with an adequate methylation pattern, which are then reprogrammed in the enucleated oocyte and develop to term. In summary, an adequate methylation status and the origin and cell cycle stage of the donor cell and its differentiation are the critical factors for a successful and efficient SCNT.

Cell Fusion

Cell fusion is a nuclear reprogramming technique that involves fusing two or more cell types to form a single identity.105 Cell fusion can generate heterokaryons or hybrids (Fig. 5B). One of the first studies in cell fusion created heterokaryons.106 These multinucleated fusion cells created by using two different cell types were nonproliferative and short lived. Early studies making heterokaryons by using chicken erythrocytes demonstrated nuclear swelling and DNA and RNA synthesis, although erythrocyte genes were still silenced.107 To solve this issue, later studies demonstrated the plasticity of the heterokaryons using muscle and amniotic cells showing that those silent genes could be activated.106,108

Several heterokaryons made by fusing mouse muscle cells with different cell types (human fibroblasts, hepatocytes, and keratinocytes) demonstrated that silent muscle genes were activated in each specific cell type of the three germ layers.106,109,110 In these studies the DNA methylation status of the heterokaryons was crucial and did not require DNA replication.111,112 Taken together, these heterokaryon experiments showed that the silent genes from different differentiated mammalian cells can be converted into other cell types, thereby showing the nuclear plasticity of this differentiated state.

The first evidence of proliferative hybrids was described by Tada and colleagues.113 They fused female embryonic germ (EG) cells with thymocytes from adult mice and demonstrated that the tetraploid cells generated were pluripotent. Moreover, the methylation status of imprinted and nonimprinted genes was similar to that found in the germline in vivo. Later, the Tada group showed that after cell fusion the acquisition of pluripotency originated from the ES cell portion.114 By contrast, the imprinted genes in the fused tetraploid cells were not demethylated as they are in the germline.

Other groups have described the generation of tetraploid hybrids using human somatic cells and human ES cells.115 When comparing generation of heterokaryons versus hybrids, heterokaryons are generated more rapidly and efficiently than hybrids, making them useful for detecting the molecular mechanisms underlying nuclear reprogramming.116,117 One possible mechanism that may account for this is the same as that used for DNA repair during in vivo epigenetic reprogramming in the germline.69,118

Spontaneous Reprogramming in Germ Cells

Mammalian PGCs are capable of undergoing spontaneous reprogramming in vitro conditions giving rise to pluripotent cells called EG cells.

Mouse and human PGCs are embryonic precursors of the germ lineage, which are restricted to form only male and female gametes. PGCs are unique cell types that show expression of some key pluripotency-specific genes and do not form chimeras when injected into blastocysts.

A cell culture system using exogenous signaling molecules (FGF2, LIF, and SCF) is capable of inducing reprogramming of mouse PGCs isolated from 8.0- to 12.5-dpc-old embryos into EG cells119 (Fig. 6A). Interestingly, the presence of FGF2 is crucial for the first 24 hours of the culture.120 This reprogramming takes 10 days; pluripotency is assessed by the ability to make chimeras afterward.120 Several mutations in DND, PTEN, PGC1, and AKT genes improve the efficiency in the generation of EG cells.121–123 It has been demonstrated that the gene BLIMP1 has an important role in preventing PGCs from dedifferentiating into a pluripotent state as well as in the upregulation of KLF4 and cMYC genes in this conversion.119 The same observation has also been published about the generation of human germlines.124,125

Direct Induced Reprogramming

In 1987 Schneuwly and colleagues found that in Drosophila, the overexpression of certain transcription factors in somatic cells could activate the expression of genes arising from another cell type.126 In the same year, another group found the same results in mammals.127 One of the breakthroughs of the recent years was published by Takahashi and Yamanaka in 2006 when they discovered that pluripotency can be
regained by several differentiated somatic cell types through the overexpression of just four transcription factors (OCT4, SOX2, cMYC, and KLF4). These cells are called induced pluripotent stem cells (iPSCs). Several factors can be changed during reprogramming such as the number of transcription factors, the strategy for the delivery, and the cell type. Depending on the donor somatic cell type, the reprogramming is achieved with different timings and efficiencies. Mouse embryonic fibroblasts can be reprogrammed in 7 to 12 days, whereas human foreskin fibroblasts take 20 to 25 days, using retrovirus technology in both cases. Compared with fibroblasts, human keratinocytes can be reprogrammed 100 times more efficiently and twofold faster.

Also, cord blood CD133 positive cells required only two factors, OCT4 and SOX2, for generating iPSCs. After choosing the donor somatic cell type, it is then necessary to select a cocktail of reprogramming factors, which usually consist of OCT4, SOX2, KLF4, and MYC, although in a few cases fewer than four factors are needed (cord blood CD133-positive cells and keratinocytes). Chromatin remodeling during reprogramming is also crucial in regaining pluripotency. So far it has been described that the use of some chemical compounds are able to alter DNA methylation or chromatin remodeling for improving reprogramming. Treatment with DNA methyltransferase inhibitors (5′-azacytidine) and histone deacetylase inhibitor (SAHA, TSA, and VPA) improves reprogramming in mouse embryonic fibroblasts. Also, other inhibitors like glycogen synthase kinase 3 (CHIR99021), Parnate (lysinospecific demethylase 1), or G9a inhibitor (BIX-01294) allow reprogramming with only two factors, reviewed in González et al. Another important step during the reprogramming process is the strategy used for gene delivery. Nowadays there are integrative delivery systems (retrovirus, lentivirus, linear DNA, and piggyback transposon) and nonintegrative systems (adenovirus, Sendai viral vectors, episomal vectors, synthetic mRNA, and proteins), each of them with pros and cons (► Fig. 6B).

From a clinical point of view, the derivation of iPSCs from patients with genetic syndromes open new opportunities for basic research into these diseases and the development of new therapeutic compounds. iPSCs can be differentiated into a variety of cell types, offering the possibility of an unlimited source of material for disease study. Recently some genetic diseases, like Parkinson disease, spinal muscular atrophy, Hutchinson-Gilford progeria syndrome, Timothy syndrome, and others have been studied using iPSCs as a model to generate differentiated cell types (neurons and cardiomyocytes) for drug testing (ROCK inhibitor, valproic acid, roscovitine, etc.).

Conclusions and Perspectives

The three processes described in this review show major differences in terms of their in vivo potential. Although dedifferentiation and transdifferentiation can be achieved in vivo, directing pluripotent cells into a new lineage is a complex process that has only been successful in vitro. So far, none of the three processes described in the current review offers the chance to generate transplantable cells in vivo, although reprogramming and transdifferentiation offer the possibility to generate autologous patient-specific transplantable cells in vitro. Moreover, reprogramming of patient-specific iPSCs offers the possibility to correct the specific mutation(s) leading to the specific disease. Interestingly, the patient’s own corrected iPSCs can be differentiated in vitro and further transplanted back into the patient. However, the
use of specific transcription factors defining target cell identity, a process generally referred to as transdifferentiation, has demonstrated the suitability of such an approach for the direct lineage conversion of human cells into several different lineages. Thus the generation of patient-specific iPSCs and the transdifferentiation of somatic patient cells have changed the way that patient-derived cell products can be applied in regenerative medicine. Both approaches allow for modeling diseases of interest in vitro to elucidate disease mechanisms and circumvent problems related to differences among species that arise when using animal models as well as decreasing patient risks.

Acknowledgments
The authors thank members of the laboratory for comments on the manuscript. Work in the laboratory of J.C.I.B. was supported by TERC-ISCIII-MINECO, CIBER, Foundation Cellex, G. Harold and Leila Y. Mathers Charitable Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust.

References
3 Steves TA, Sussex IM. Patterns in Plant Development. Cambridge, UK: Cambridge University Press; 1989
16 Echeverri K, Clarke JD, Tanaka EM. In vivo imaging indicates muscle fiber dedifferentiation is a major contributor to the regenerating tail blastema. Dev Biol 2001;236(1):151–164
17 Hay ED. Microscopic observations on muscle dedifferentiation in regenerating Ambystoma limbs. Dev Biol 1959;1:555–585
30 Bicknell KA, Coxon CH, Brooks G. Can the cardiomyocyte cell cycle be reprogrammed? J Mol Cell Cardiol 2007;42(4):706–721


Hamilton B, Feng Q, Ye M, Welstead GG. Generation of induced pluripotent stem cells by reprogramming mouse embryonic fibroblasts with a four transcription factor, doxycycline inducible lentiviral transduction system. J Vis Exp 2009;(33):


